HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Animal in vivo model of arrhythmia for genes target identification for 5-amino-exo-3-azatricyclo[5.2.1.0(2,6)]decan-4-one].

Abstract
The goal of the current work is to study the molecular mechanisms underlay the action of 5- amino-exo-3-azatricyclo[5.2.1.0(2,6)]decan-4-one (P-11) with combined antiarrhythmic, nootropic, anti-inflammatory and anaesthetic activities. The aconitine-induced experimental rat model of cardiac arrhythmia has been used in our study. Aconitine was administered once intravenously in a dose 50 microg/kg whereas experimental animal group received P-11 in a dose 0.3 mg/kg (the compound was injected intravenously 2 min before acute aconitine treatment). Expression macroarray (Atlas Rat cDNA Expression Array, #7738-1; BD Biosciences) was used to identify the target genes for P-11 compound. Comparative analysis of changes in the status of expression of genes in the heart of rats induced by P-11 against the simulated in vivo arrhythmia identified 16 genes that reproducibly alter the level of expression.These genes encode the extracellular matrix proteins (glypican 1, Gpc1; tissue inhibitor of metalloproteinase 2, 3, Timp2, Timp 3); intracellular signaling molecules (rho GTPase activating protein 7, Dlc1; protein tyrosine phosphatase 4a1, Ptp4a1; phosphodiesterase 4D, PDE4D; PI3-kinase regulatory subunit alpha, PIK3R1; guanine nucleotide binding protein alpha 12, Gna12) and protein of intermediate junctions (junction plakoglobin, Jup), proteins involved in glycolysis (phosphofructokinase I, Pfk1) and hemostasis (tissue plasminogen activator, Plat), plasma membrane transporters (Solute carrier family 16, member 1, Slc16a1; ATPase, Na+/K+ transporting, Atp1a), and ets. (c-fos protooncogene, c-fos; telomerase protein component 1, tlp; Annexin 1, anxa 1). Thus, the data about the selective effect of P-11 on genes whose products are involved in the aritmogenesys mechanisms, allow us to consider this compound as a promising means of pathogenetically oriented pharmacotherapy of cardiac arrhythmias.
AuthorsIu V Vakhitova, E I Antipina, R S Yamidanov, R Iu Khisamutdinova, F S Zarudiĭ, N Zh Baschenko, V A Dokichev, Iu V Tomilov, O M Nefedov
JournalBioorganicheskaia khimiia (Bioorg Khim) 2011 Nov-Dec Vol. 37 Issue 6 Pg. 821-9 ISSN: 0132-3423 [Print] Russia (Federation)
PMID22497081 (Publication Type: English Abstract, Journal Article)
Chemical References
  • 5-amino-exo-3-azatricyclo(5.2.1.0(2,6))decan-4-one
  • Anti-Arrhythmia Agents
  • Aza Compounds
  • Extracellular Matrix Proteins
  • Intracellular Signaling Peptides and Proteins
  • Membrane Transport Proteins
  • Aconitine
Topics
  • Aconitine (administration & dosage)
  • Animals
  • Anti-Arrhythmia Agents (chemical synthesis, pharmacology)
  • Arrhythmias, Cardiac (drug therapy, genetics)
  • Aza Compounds (chemistry, metabolism)
  • Disease Models, Animal
  • Extracellular Matrix Proteins (genetics, metabolism)
  • Gene Expression (drug effects)
  • Intracellular Signaling Peptides and Proteins (genetics, metabolism)
  • Membrane Transport Proteins (genetics, metabolism)
  • Oligonucleotide Array Sequence Analysis
  • Rats

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: